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Pulmonary Hypertension (PH) associated to chronic respiratory diseases is currently classified in the 3rd group, as a
mild to moderate form of pre-capillary PH that progressively complicates the prognosis of associated pulmonary
disease. In clinical practice, however, some unresolved issues in the respiratory PH should be considered: 1) the PH
heterogeneity in some respiratory diseases, such as Chronic Obstructive Pulmonary Disease (COPD), where the
prevalence of unrecognized left heart disease, or chronic pulmonary thromboembolism may change the clinical
classification; 2) the combining form of severe PH which often is not correlated to chronic ventilator impairment,
while outcome is strictly related to pulmonary haemodynamics. The recognition of out of proportion respiratory PH
in several chronic respiratory diseases which include COPD, Idiopathic Pulmonary Fibrosis (IPF), Combined Pulmonary
Fibrosis and Emphysema, Obstructive Sleep Apnea (OSA), Obesity Hypoventilation Syndrome (OHS) may be important
for a comprehensive clinical classification of severe respiratory PH, as well as, for the inclusion of these patients in
randomized clinical trials on PH targeted therapy.
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Review
Clinical disease classification is an important tool for
physicians, in order to distinguish severity and to diffe-
rently manage a same disorder that can be found in
multiple clinical conditions; this is particularly true for
pulmonary hypertension [1,2]. Pulmonary Hypertension
(PH) is a relatively frequent pathophysiological and
haemodynamic state that can be detected in almost 37
clinical syndrome comprising multiple clinical condi-
tions, including chronic left heart disease and lung dis-
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stated.clinical classification are the separation of pulmonary
arterial hypertension (Gr 1) (a rare disease, with a cur-
rently available efficacious treatment in term of life-
savings) from other forms of PH associated to various
disorders (Gr 2 and Gr 3), where specific pharmaco-
logical treatments for PH are discouraged, while the best
management is represented by the treatment of associ-
ated disease. Actually Pulmonary Arterial Hypertension
(PAH) includes different forms that share a similar clin-
ical picture and virtually identical pathological changes
of the distal pulmonary arteries which may represent the
right substrate for specific therapy. Furthermore, the
clinical classification allows the recognition of chronic
thromboembolic PH, the only form surgically treatable
(Gr 4), and a miscellaneous group of PH with unclear
and/or multifactorial mechanisms (Gr 5) that may in-
duce specialists to seek for important associations, such
as ematologic, metabolic, or systemic diseases. Recently,
the current 6 groups classification has given the oppor-
tunity to adhere to an easy stepwise diagnostic algo-
rithm. There are, however, some limitations for clinicaltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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homogeneous epidemiologic distribution with a high
prevalence (85% of all PH cases) of Gr 2 and Gr 3 PH,
compared to the other groups. It is likely that improving
the concentration of PH in a same group may increase
the clinical variability with differences in PH phenotype,
making clinical evaluation more difficult for the greater
interference of confounding factors related to comorbid-
ities, such as age, increasing number of mixed forms,
or a grey zone related to the selection of pulmonary
haemodinamics criteria. Remarkably, this phenomenon
has been reported also for PAH in the recent experi-
ence of US and UK registries. Compared to other an-
alyzed comorbidities in PAH patients, hypertension,
obesity, diabetes, and Chronic Obstructive Pulmonary
Disease (COPD) were associated with significantly worse
6-minute walk distance (6MWD); obesity and COPD with
worse functional class; and diabetes and COPD with
increased risk of death [3]. Likewise, a grey zone of
patients with Pulmonary Capillary Wedge Pressure
(PCWP) 16 to 18 mm Hg who were diagnosed and
treated for PAH has been analyzed: they were older,
heavyweight, and more likely to have comorbidities as-
sociated with left ventricular diastolic dysfunction at
diagnosis than those with PCWP ≤ 15 mm Hg. Five-
year survival rates were similarly low for all PCWP
subgroups [4]. Another report examined the influence
of age on phenotypes of incident pulmonary arterial
hypertension and showed the changes in demographics
and epidemiology over the past decade in a national
setting, suggesting that there may be two subtypes of
patients: the youngest subtype with more severe
hemodynamic impairment but better survival, and the
oldest subtype which has more comorbidities [5].
The impact of coexistent left heart disease in COPD
should be taken into account in clinical practice, as car-
diovascular disease increases morbidity and mortality
significantly. In one recent study, transthoracic echocar-
diography performed prospectively in more than 300
patients with COPD 3 months after discharge from
the hospital after an acute exacerbation demonstrated
significant cardiac alterations in 64% of patients: 27%
left- and 48% right-heart disorders with a frequency
of PH around 19%. Interestingly, left ventricle systolic
dysfunction, left ventricle diastolic impairment, and left
atrial dilatation were present in 29%, 12%, and 13% of
the COPD patients respectively. Noticeably, echocar-
diographic abnormalities were unrelated to COPD sever-
ity [6]. The prevalence and the prognostic implications of
the simultaneity of left ventricular dysfunction in COPD
patients and airway obstruction in Congestive Heart
Failure (CHF) patients were shown in another recent
prospective study which included stable ≥ 60-yr-old pa-
tients with echocardiographic confirmed CHF (n = 201) andstable ≥ 60-yr-old patients with clinically and spirometry-
confirmed COPD (n = 218). Previously unrecognized left
ventricular dysfunction occurred in 17% of COPD with a
significant influence on the survival rate [7].
The coexistence of emphysema and pulmonary fibrosis
in the same patient results in a clinical syndrome, known
as combined pulmonary fibrosis and emphysema (CPFE),
that is characterized by dyspnea, upper-lobe emphysema,
lower-lobe fibrosis, and abnormalities of gas exchange
almost only in male older smokers. This syndrome is fre-
quently complicated by pulmonary hypertension with in-
creased mortality [8].
A retrospective multicentre study in 40 patients re-
ported severe PH in CPFE patients and 60% survival at
one year. Surprisingly, lung volumes and flows were rela-
tively preserved while exercise capacity resulted severely
compromised; moreover, haemodynamics were the most
significant prognostic indexes [9].
PH is a well-recognized complication of interstitial
lung disease, including idiopathic pulmonary fibrosis
(IPF) and its prevalence has been estimated from 32% to
85%. There is a highly significant difference between sur-
vival of IPF patients with and without PH [10]. Hypoxia,
destruction of pulmonary vascular bed or fibroprolifera-
tive phenomena might be important mechanisms in in-
dividual patients. However, the correlation of PH with
forced vital capacity (FVC) is weak and patients with se-
vere PH and still preserved lung volumes could also be
seen [11]. Severe pulmonary hypertension can occur in
idiopathic NSIP, even in the absence of advanced radio-
graphic changes, especially when DLCO is severely re-
duced [12].
Out-of-proportion PH is defined as the unjustified
increase in PH that is observed in patients affected by
different types of parenchymal lung disease [COPD, IPF,
Obstructive Sleep Apnea, (OSA), Obesity Hypoventilation
Syndrome (OHS), etc.]. The term ‘out-of-proportion
PH’ was introduced recently into the field of PH. Until
few years ago the term ‘pulmonary heart’ was used to
indicate the development of PH-correlated parenchy-
mal diseases and presence of chronic hypoxia leading
to chronic respiratory failure and, as a consequence,
right heart failure. But in the last few years better un-
derstanding of the mechanisms underlying structural
remodeling of the pulmonary vascular bed raised the
doubt that all can be explained by the presence of pul-
monary heart. Indeed, some patients can develop ex-
tremely high pulmonary artery pressure that cannot be
explained by hypoxia and remodeling of the pulmo-
nary vascular bed alone. Due to an increasing use of
right heart catheterization for selection of candidates
for lung transplantation, a number of patients affected
by parenchymal lung diseases (often accompanied by
minor lung impairment on lung function tests and/or
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come to the attention of doctors. In these patients the
development of moderate to severe PH, that cannot be
explained by the degree of parenchymal lung disease
and hypoxia has been defined out-of-proportion PH,
and an arbitrary value of PAPm> 35 mm Hg has been
established to identify these patients. However, the use
of the term out of proportion PH is questionable. In-
deed, a direct relationship between ventilator impair-
ment and pulmonary haemodinamics has not been
documented in COPD yet. Instead severe respiratory
PH phenotype seems a more appropriate term, accord-
ing to recent data based on ASPIRE Registry [13]. In
this study 59 patients with COPD and severe pulmonary
hypertension had significantly lower carbon monoxide dif-
fusion, less severe airflow obstruction but not significantly
different emphysema scores on computed tomography
compared to 42 patients with mild–moderate pulmonary
hypertension. 1- and 3-year survival for severe pulmonary
hypertension, at 70% and 33%, respectively, was inferior
to 83% and 55%, respectively, for mild–moderate pul-
monary hypertension. Moreover, mixed venous oxygen
saturation, carbon monoxide diffusion, World Health
Organization functional class and age, but not severity of
airflow obstruction, were independent predictors of out-
come. Remarkably, improvement in functional class and/
or fall in pulmonary vascular resistance > 20% following
targeted treatment identified patients with improved
survival.
The diagnosis would be pulmonary hypertension ra-
ther than pulmonary arterial hypertension; in fact in-
creased pressures are the result of another disease
rather than of diseased arteries. Nonetheless, patients
can have both idiopathic pulmonary arterial hyperten-
sion and interstitial lung disease contemporaneously.
An expert on pulmonary hypertension is required to
evaluate such patients and make the correct diagnosis. If
through the examination with right heart catheterization
the specialist evaluates that the pulmonary hyperten-
sion is out of proportion with respect to the lung dis-
ease, the patient can be treated. In brief, mild lung
disease usually does not advance to severe pulmonary
hypertension.
Pulmonary hypertension and COPD
COPD, defined as a persistent and progressive airflow
obstruction, is complicated by numerous comorbidities
or associated conditions, as also by frequent episodes of
acute exacerbation. Generally, alterations are mainly lo-
cated in the small airways. Pulmonary hypertension due
to chronic respiratory disease and/or hypoxemia repre-
sents Group 3 of the Dana Point (2009) clinical classifi-
cation of PH [14]. This group includes forms of PH due
to COPD, pulmonary fibrosis and/or combinedpulmonary diseases, in other words chronic infections in
which signs of emphysema are visible in the upper
lobes and fibrosis in the lower. PH due to respiratory
diseases is considered a hemodynamic alteration asso-
ciated to, and a consequence of, the primary disease,
as distinct from the idiopathic form that represents the
true disease in which the pulmonary vessels are in-
volved from the very outset.
In terms of definition it is important to underline the
meaning of ‘out of proportion’. Cut-off values > 35 and/
or > 40 mmHg of PAPm are employed in the literature
to define out-of-proportion respiratory PH. This defin-
ition was used in the recent guidelines of the European
Respiratory Society/European Society of Cardiology [15].
Numerous studies have documented the clinical impact
of PH on mortality in COPD patients. Although there
is not unanimous agreement about the definition of
‘out-of-proportion PH’, as a general rule it is considered
to be any value of PH in COPD patients with mild-
to-moderate ventilatory impairment (forced expiratory
volume in 1 sec [FEV1] > 50% predicted) or a mPAP >
40 mm Hg in the presence of severe ventilatory def-
icit but without comorbidities. It should also be noted
that in COPD patients levels of mPAP between 21
and 24 mm Hg are considered a pre-PH condition
and further studies are required to establish the clin-
ical impact of this range. By ‘chronic pulmonary heart’
definition it is meant hypertrophy and dilation of the
right ventricle secondary to PH due to chronic pul-
monary disease. However, this term is inappropriate in
clinical practice both because the observation of right ven-
tricle anomalies varies according to the method used and
because peripheral edema, a clinical surrogate of chronic
pulmonary heart, could appear in COPD patients with
normal or low central venous pressure. Exercise-induced
PH could be used in clinical research but at the moment
there is no consensus about the definition. In conclusion,
at present PH is defined as resting pulmonary pressure >
25 mm Hg, pulmonary capillary wedge pressure < 15
mm Hg, and/or a reduced cardiac output as measured
hemodynamically in COPD patients.
Pathogenesis of PH secondary to COPD
PH associated to COPD is of a pre-capillary type with low
or normal cardiac output and is in particular determined
by pulmonary vascular remodeling that provokes an in-
crease in the pulmonary vascular resistance (PVR). Char-
acteristically, it has been shown that cigarette smoking
causes vascular remodeling even in early phases of the dis-
ease, promoting endothelial dysfunction and airways in-
flammation. Chronic alveolar hypoxia is responsible for
the remodeling of the pulmonary arterioles in particular
in people living at high altitude; thus, in COPD patients
pulmonary vascular remodeling seems to be the leading
Table 1 Prevalence of PH in OSA patients
Study Sample size PH prevalence (%)
Schroeder et al. [22] 22 59
Tilkian et al. [23] 12 67
Fletcher et al. [24] 24 79
Podszus et al. [25] 65 20
Weitzenblum [26] 46 20
Krieger et al. [27] 114 19
Sajkov et al. [28] 27 41
Laks et al. [18] 100 42
Chaouat et al. [29] 220 17
Sanner et al. [30] 92 20
Bady et al. [31] 44 27
Sajkov et al. [32] 32 34
Alchanatis et al. [33] 29 21
Arias [34] 23 43
Dumitrascu [35] 45 20
Modified from [36].
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have been described even in the absence of hypoxemia
and long term oxygen therapy does not modify the course
of PH in COPD. Nonetheless, local inflammation at the
level of the small pulmonary arteries associated to hypox-
emia can contribute to pulmonary vascular remodeling.
Hemodynamic characteristics
Generally PH in COPD is pre-capillary at rest, but PH
with elevated capillary pressure is frequently observed in
COPD patients with associated emphysema and/or in
the presence of comorbidities such as left heart dysfunc-
tion. The peculiar nature of the right ventricle, that
shows capacity to adapt to the rising afterload and there-
fore a slow progression towards a functional impairment
has to be expected. This feature would explain the well-
preserved contractility of the right ventricle at rest and
in phase of clinical stability as well as the slow develop-
ment of PH. In fact in COPD patients and other patients
with chronic lung disease, PH is usually of a mild-
moderate level: this constitutes an important distinction
from the other forms of PH, those of Groups 1 or 4 of
the Dana Point classification. Even if PH is mild or mod-
erate at rest, then PAP increases markedly during sleep,
physical exercise and, in particular, during exacerbations.
Approximately 10-20% of COPD patients at the ad-
vanced stage present severe PH with PAP > 35 mm Hg,
and this is observed in 3 clinical conditions: a) in pa-
tients with severe hypoxemia and hypercapnia associated
to severe airflow limitation in whom an increase in rest-
ing mPAP can be seen in clinically stable conditions;
b) in patients with associated comorbidities such as
chronic venous thromboembolism, severe left heart
disease or an associated restrictive pulmonary disease;
and c) in patients with modest functional limitation
associated to severe hypoxemia and hypocapnia. This
last condition is defined as out-of-proportion PH. The
hemodynamic alterations observed in this form of IP are
similar to those observed in the idiopathic form. Recent
data from the National Emphysema Treatment Trial indi-
cate that the finding of severe PH at rest is a rare event in
emphysema in the absence of comorbidities.
Clinical impact
The pathogenetic mechanisms underlying dyspnea in
COPD patients consist largely in hyperinflation, increased
ventilatory demand, muscle weakness and, in more severe
patients, hypoxemia and hypercapnia. Nevertheless, the
impact of PH on symptoms during exercise is not well
established yet, nor it is established if modest increases in
mPAP contribute to dyspnea in the course of exercise. In
fact, a recent study compared patients with COPD and
severe PH with mild-moderate hyperinflation to patients
with COPD and mild PH associated to more severeairways limitation who manifested a greater exercise in-
tolerance. More recently it has still been shown that
COPD patients with mPAP> 40 mm Hg present a reduced
circulatory reserve at end of exercise in contrast to venti-
latory reserve exhaustion observed in COPD patients with
less severe PH. These findings suggest that lung hemo-
dynamics plays an important role in exercise-related dys-
pnea in COPD patients with severe PH (mPAP>
40 mm Hg) and not in patients with mild-moderate PH.
Exercise capacity
Retrospective studies have documented that elevated
levels of mPAP are associated to a reduced distance
walked in meters on the 6MWT [16] and to a lower
maximal power during incremental cardiopulmonary ex-
ercise test compared to patients with airways function
limitation but mild PH [17]. During the obstructive event
the transmural pulmonary arterial pressure is modified in
inverse proportion to the level of hypoxia, even if the
addition of O2 does not modify this condition.
PH associated to OSA
Pulmonary hypertension has been demonstrated in ap-
proximately 17-42% of patients with obstructive sleep
apnea syndrome (OSAS) [18,19]. Determining factors in
the onset of pulmonary hypertension seem to be PaO2,
PaCO2 and FEV1. Studies on animal cell lines have docu-
mented that intermittent hypoxia acts as a far more potent
stimulus than continuous hypoxia on the activation of mul-
tiple transcription factors; among these we find hypoxia-
inducible factor-1 (HIF-1), with its second messengers,
erythropoietin and vascular endothelial growth factor
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sible for the structural and pressure modifications [20].
The association of pulmonary hypertension due to
hypoventilation and exercise capacity, and the haemo-
dynamic and functional changes, under non-invasive ven-
tilation, has been recently characterized with the presence
of severe PH, increase in pro-BNP, and low exercise cap-
acity at baseline, which improved significantly after three
months of non invasive ventilation [21]. The PH preva-
lence estimated in OSA patients is shown in Table 1.Pulmonary hypertension in obesity hypoventilation
syndrome
Obesity places a significant load on the respiratory sys-
tem, affecting lung volumes, respiratory muscle function,
work of breathing, and ventilatory control. Despite this,
most morbidly obese individuals maintain eucapnia.
However, a subgroup of morbidly obese individuals will
develop chronic daytime hypercapnia, described as the
Obesity Hypoventilation Syndrome (OHS).
OHS is defined as a disease characterized by:
1. Obesity: BMI ≥ 30 kg/m2
2. Chronic alveolar hypoventilation
3. Daytime (awake) hypercapnia (PaCO2 ≥ 45 mm Hg)
4. (OSA) sleep respiratory disorders (AHI ≥ 5 with or
without hypoventilation during sleep) present in 90%
of cases; hypoventilation during sleep (AHI < 5)
present in 10% of cases.
The prevalence of estimated PH in OHS is very high,
and is between 59 and 88% [37]. Patients with OHS have
a lower quality of life with increased health-care ex-
penses and are at a higher risk for the development of
pulmonary hypertension and early mortality compared
to eucapnic patients with sleep-disordered breathing.
Despite the significant morbidity and mortality associ-
ated with this syndrome, it is often unrecognized and
treatment is frequently delayed.Conclusions
Pulmonary hypertension associated to respiratory diseases
is a multifactorial disorder which may complicate, and ser-
iously modify, the prognosis of the principal disease. The
management and the treatment of this important compli-
cation must be evaluated by a team of specialists, includ-
ing cardiologists, pulmonologists and rheumatologists.
This small review showed the most common disorders
associated to pulmonary hypertension, in which the phys-
ician has the pivotal role to investigate as soon as possible
the presence of this complication, in order to early identify
the phenotype associated to the worst outcome.Abbreviations
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